Source: Myeloma – Hematology Advisor
Researchers sought to determine whether ixazomib plus daratumumab and low-dose dexamethasone would be effective in intermediate-fit patients with MM.
Read More
Recent Content
- Cytokine-responsive T- and NK-cells portray SARS-CoV-2 vaccine-responders and infection in multiple myeloma patients
- Advances in the pathogenesis of multiple myeloma bone disease
- Association Between Circulating 25-Hydroxy Vitamin D Receptor and Molecular Response in Multiple Myeloma
- Clinician preferences on treatment of smoldering myeloma: a cross-sectional survey
- Efficacy of different regimens and prognostic factors in patients with first relapsed multiple myeloma treated after front-line bortezomib, cyclophosphamide, and dexamethasone
- Impact of autologous stem cell transplantation (ASCT) on progression free survival (PFS) in newly diagnosed multiple myeloma patients (NDMM) with high risk cytogenetic abnormalities
- Side Effects of Bone Strengtheners: Multiple Myeloma
- Clarithromycin overcomes stromal cell-mediated drug resistance against proteasome inhibitors in myeloma cells via autophagy flux blockage leading to high NOXA expression
- Plasma levels of BCMA-positive extracellular vesicles correlate to response and side effects in myeloma patients treated with belantamab-mafodotin
- Apparent diffusion coefficient measurements of bone marrow infiltration patterns in multiple myeloma for the assessment of tumor burden – a feasibility study